Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.
The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.29 Increased by +33.51% | - |
| Mar 17, 25 | -0.27 Increased by +40.16% | - |
| Nov 7, 24 | -0.44 Increased by +10.71% | - |
| Aug 8, 24 | -0.45 Increased by +55.12% | - |
| May 9, 24 | -0.43 Decreased by -425.94% | - |
| Mar 19, 24 | -0.46 Decreased by -368.27% | - |
| Nov 9, 23 | -0.49 Decreased by -445.56% | - |
| Aug 9, 23 | -1.00 Decreased by -901.40% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -709.55 K Increased by +26.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -618.00 K Increased by +40.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -986.03 K Increased by +3.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.01 M Increased by +39.40% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -971.00 K Increased by +29.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -1.03 M Increased by +36.52% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.02 M Increased by +30.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.67 M Decreased by -7.91% | Decreased by N/A% Decreased by N/A% |